woodstock135
13 years ago
Investment Industry Regulatory Organization of Canada - Trading Halt - Stem Cell Therapeutics Corp. - SSS
VANCOUVER, Mar 18, 2011 (Canada NewsWire via COMTEX News Network) --
The following issues have been halted by Investment Industry Regulatory Organization of Canada (IIROC):
Issuer Name: Stem Cell Therapeutics Corp. TSX-V Ticker Symbol: SSS Time of Halt: 9:58 E.S.T. Reason for Halt: Company Request Pending News
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/March2011/18/c4329.html
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC)
SOURCE: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
<p>IIROC Inquiries (416) 646-7299 - *Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.</p>
Copyright (C) 2011 CNW Group. All rights reserved.
woodstock135
13 years ago
IIROC issues proposal for Single-Stock Circuit Breakers and invites public comment
TORONTO, Nov. 18 /CNW/ - The Investment Industry Regulatory Organization of Canada (IIROC) has issued for public comment a proposal to implement single-stock circuit breakers to address rapid, significant and unexplained price movement in a security that calls into question whether there is a "fair and orderly" market for that security. The proposal builds on the approach followed by IIROC when instituting coordinated regulatory halts across all Canadian marketplaces that trade a particular security.
Under IIROC's proposal, single-stock circuit breakers would apply to all securities listed on an exchange in Canada, including securities inter-listed in Canada and the U.S. When a stock price increases or decreases past a certain threshold, the circuit breaker would trigger a trading halt to provide a pause.
The proposed halt would last five minutes for TSX-listed shares, with the possibility of an extension in the case of a severe order imbalance. The proposed halt for stocks listed on the TSX-Venture and CNSX exchanges is 10 minutes to account for lower levels of liquidity.
Shortly after the May 6 Flash Crash, the Canadian Securities Administrators and IIROC together announced they had begun a comprehensive analysis of the events of the crash, including a review of the "appropriateness of the existing circuit breaker policy." During the crash, markets in the US and Canada experienced extreme volatility, with some stocks quickly experiencing dramatic price declines and rallies.
Under the Universal Market Integrity Rules (UMIR), IIROC has the authority to delay, halt or suspend trading at any time where it is considered appropriate and in the interest of a fair and orderly market. The regulatory halt may apply market-wide or to particular securities. This allows for the imposition of manual halts to address unexplained price movements in a single security. However, current practice is not adequate where there is a need to halt trading in multiple securities across multiple marketplaces, all in a short window of time.
The thresholds under the proposal distinguish between more liquid and less liquid securities. The proposed thresholds are:
•For TSX-listed securities, a halt would be initiated where a stock's price increases or decreases by at least 10 per cent or 10 trading increments, whichever is greater, over a five-minute period.
•For securities listed on the TSX-V or CNSX, a halt would be initiated where a stock's price increases or decreases by at least 20 per cent or 20 trading increments, whichever is greater, over a 10-minute period.
The circuit breakers would be in effect from 9:50 am to 3:40 pm ET.
The Single-Stock Circuit Breaker Proposal is intended to operate as part of a multi-tiered approach for controlling short-term, unexplained price volatility:
I. The first set of controls is at the market participant level where, under UMIR, firms are required to comply with their existing trade supervision obligations.
II. The second set of controls would be effective marketplace volatility controls with consistent objectives across marketplaces.
III. The single-stock circuit breaker would represent the third level of controls.
Both market participant obligations and marketplace level controls should be designed to detect 'erroneous orders' prior to execution. Each of the above-noted elements plays an important role in the overall control framework designed to mitigate the risks associated with unexplained short-term price movement and to promote fair and orderly markets.
The proposal calls for a three-stage process consisting of initial consultation and development, implementation and review/evaluation.
Public Comment Period: The proposal is being issued for a 60-day comment period.
Once comments are received from the public, marketplace participants and the Canadian Securities Administrators, IIROC will review the comments and, as appropriate, revise the Single-Stock Circuit Breaker Proposal. Comments should be directed to:
Timothy Ryan,
Director, Market Regulation Policy,
Investment Industry Regulatory Organization of Canada,
Suite 900 145 King Street West, Toronto, Ontario. M5H 1J8
Fax: 416.646.7265 e-mail: tryan@iiroc.ca
janetcanada
13 years ago
Good morning TA4U, thankyou for taking the time to explain your way........
Since I read this I think the market is getting more and more a "controlled racket" ........
Wishing you a great day
janet
HIGH FREQUENCY TRADING:
http://blogs.wsj.com/deals/2010/10/11/high-frequency-trading-what-you-missed-on-60-minutes/
60 Minutes: HAL9000
Mark , TraderMark
Published 10/12/2010 - 8:30 a.m. EST Rate This Article:
0
ABOUT THE AUTHOR
Mark
Website:
http://www.fundmymutual...
Email:
Email
Not a ton of new ground in this 60 Minutes piece if you have been following the HFT trend the past few years, but probably a good overview for the typical 60 Minutes viewer who is not exposed to the financial markets day in and day out. Joe Saluzzi [Jun 18, 2009: Joe Saluzzi Comments on HAL9000] gets a lot of face time here. What was amazing is not one soul in the HFT community (ok, they found one) would grant an interview, even the exchanges like BATS or DirectEdge. Once again the oft used excuse of "we provide liquidity" is why we should be happy our orders are front run - of course they provide liquidity, except when liquidity is really needed i.e. May 6th.
It may surprise you to learn that most of the stock trades in the U.S. are no longer being made by human beings, but by robot computers capable of buying and selling thousands of different securities in the time it takes you to blink an eye.
These supercomputers - which actually decide which stocks to buy and sell - are operating on highly secret instructions programmed into them by math wizards who may or may not know anything about the value of the companies that are being traded.
It's known as "high frequency trading," a phenomenon that's swept over much of Wall Street in the past few years and played a supporting role in the mini market crash last spring that saw the Dow Jones Industrial Average plunge 600 points in 15 minutes.
Most people outside of the industry know very little, if anything, about it. But the Securities and Exchange Commission and members of Congress have begun asking some tough questions about its usefulness, potential dangers, and suspicions that some people may be using computers to manipulate the market.
Legal Disclaimer and Risk Disclosure:
The opinions listed on this blog are for educational purpose only. You should do your own research before making any decisions. This blog, its affiliates, partners or authors are not responsible or liable for any misstatements and/or losses you might sustain from the content provided.
TA4U
13 years ago
Hi again Janet.
Just read your post...
I feel compelled to answer. And please beleive me, I am not a bragger, nor a salesperson.
I was once where you are now, reading Stockhouse posts, beleiving in the co's I had invested in. There was always a good reason not to sell/take my profits. Very few of my investments came to fruition... In fact, the only thing growing was my frustration...
I then turned to TA. I learned to trade without even knowing what a company was about. Buying the dips and selling the highs. Money in motion. Now dont go beleiving I made (make) millions. Not at all. But if I compare my track record to that of 10 years back, I am much better off, and no nightly anguishing anymore...
As for SSS itself now, well perhaps I should avoid commenting it tonite...
One last word: I do not come here often, so if you want to reach me, better go through my normal email.
Take care.
woodstock135
14 years ago
This is from another board. Posted yesterday by KayDay.
Tonight's call was very interesting and positive. It was nice to be able to ask questions and get comprehensive answers... though it was hard to hear everything with people joining and leaving every couple of minutes. I did walk away with a few points. Note: I couldn't take notes because I was driving so please feel free to correct any errors... I will leave details to others.
1. They have a plan and an offer of intent on the table. Alan couldn't name the company but gave details about what the offer entailed. He only just got the offer after the release on Friday and stressed that this group approached SSS. There is interest and they would partner sooner rather than later. I will leave it to someone else who took notes to explain the details.
2 They are acutely aware of the financial state of the company but have many options that will finance all of our trials including stroke. I asked about dilution and they said that it is always an option but at a higher sp... he went on to say that with the current plan there may not be a need to raise any more money and therefore no need to dilute. In other words the current plan could give them all they need to continue.
3. TBI trials are accounted for financially and should have their first patient by year end with the trial lasting 6-8 months. The US army is very interested as is their contact in the States who has himself suffered from TBI. This is something they are very excited about.
4. The end of phase II meeting is a formality and they are confident that they will move forward. The FDA doesn't grant these meetings to everyone. SSS had to submit material before hand for the FDA to allow a meeting, the fact that we have a date set is very positive. They did not have to ask for a meeting but wanted to make sure that they did everything by the book and wanted to check this off their list. With the current results the FDA should be happy and SSS has someone on their team in place who has dealt extensively with the FDA who will accompany them and be present at the meeting.
5. I asked Alan if SSS was under the impression that everyone in the stroke trial would have OT and he said YES. They were very surprised to learn that not everyone got OT as a standard treatment protocol. Our drug without OT is like steroid use without lifting weights.
6. Lastly, why did Dean Peterson buy 10% of the company... he had shares before the drop and has followed the company for a long time. When the news in May came out and he heard all the negative information and feedback, he felt that it didn't add up. Then reading the results, he didn't find them them that bad and decided to take a closer look... with DD he decided to buy more shares and wanted to get involved formally with the company.
These are the points that stuck with me and some of the questions I asked, I'm sure I have forgotten lots so I will depend on others to share. This is all from memory.
All in all, I walked away excited and feel like my decision to keep my shares and buy more was a good one. They have a solid team in place committed to treat this like a business with the priority being the product and the valuation. I only wish that they would release all this to the public in a well worded press release... what I heard tonight is nothing like the releases we have been getting. In the end, I agree with Alan ... for where we are in our trial, with the successes we have achieved, and the drugs and IP we have... SSS is grossly undervalued.
woodstock135
14 years ago
Stem Cell Therapeutics Corp. Announces Funding of the Traumatic Brain Injury (TBI) Clinical Study and Issuance of Stock Options
CALGARY, ALBERTA, Aug 30, 2010 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) wishes to announce budgetary approval of the SCT-sponsored investigator-lead Phase IIa study entitled "A Phase IIa, Single Center, Open Label Study to Characterize the Safety of Human Chorionic Gonadotrophin (hCG) and Epoeitin Alpha (EPO) in Traumatic Brain Injury". After strategic discussions between management and the Board of Directors a decision was made to go forward with the TBI clinical study. SCT will provide the funding necessary to complete the enrollment of 10 TBI patients in a single center open label study, lead by Dr. David Zygun, to characterize the safety of hCG and EPO in traumatic brain injury. A series of efficacy endpoints are part of the trial design in order to access various aspects of neurological status.
Dr. Alan Moore, President and CEO of SCT said "We are excited to fund this study, which is a significant milestone, and demonstrates the Company's commitment to the advancement of our programs. This is an important step for SCT as we move forward and highlights our dedication to prospering in the biotechnology area. We are in the process of evaluating all our programs and plan to make announcements as decisions are made."
The Company also wishes to announce the issuance of stock options to the directors of the Company. SCT has issued an aggregate of 1,550,000 stock options to three of the Company's Board of Directors at an exercise price of C$0.10 per share. These options will expire no later than August 27, 2015 subject to applicable vesting provisions. These options were awarded in accordance with the Company's Stock Option Plan.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:Stem Cell Therapeutics Corp.Alan Moore, PhDPresident and CEO403-245-5495 ext.224amoore@stemcellthera.comStem Cell Therapeutics Corp.Angelika Goncalves DaSilvaOperations ManagerPhone: 403-245-5495 ext. 221adasilva@stemcellthera.comwww.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com mailto:adasilva@stemcellthera.com http://www.stemcellthera.com
Copyright 2010 Marketwire, Inc., All rights reserved.
woodstock135
14 years ago
The news is not good!
CALGARY, ALBERTA--(Marketwire - June 25, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) announces the following updates:
Ongoing Stroke Trial Analysis
On May 25, 2010, the Company announced top-line results for the modified REGENESIS-Phase IIb stroke trial, a placebo controlled, double blinded, 3:1 randomized clinical study that enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. SCT reported that the top-line analysis for this clinical trial of NTx(R)-265 in acute stroke showed that there was substantial improvement in the primary efficacy endpoint (absolute change in NIHSS) in both placebo treated patients and those receiving NTx(R)-265, with no statistical differences between the groups.
After further analysis of the trial results, management has been unable to determine a definitive explanation for the unexpectedly large placebo effect encountered in the modified REGENESIS-Phase IIb stroke trial. Further analysis has, however, indicated that some of the secondary endpoints that were also measured as part of the trial demonstrate a trend that shows greater efficacy in those patients who received the NTx(R)-265 therapy versus those who were given the placebo. None of these secondary endpoints had sufficient patient populations to demonstrate statistically significant differences; nevertheless the trends are considered by management to be encouraging. Analysis of the trial results is ongoing and all calculations are subject to validation in the final report which is expected to be completed by the end of August.
In light of these positive trends, and the excellent safety profile for NTx(R)-265 as demonstrated by the modified REGENESIS-Phase IIb stroke trial, management of the Company believes that it would be worthwhile to proceed to an end-of-Phase II meeting with the FDA in which they will seek approval to proceed with a Phase III stroke study for NTx(R)-265. Management's objective is to have such meeting in October of this year. There can be no assurance that the FDA will grant approval for a Phase III stroke trial.
Cost Cutting Program
Even if the Company is successful in obtaining FDA approval to conduct a Phase III stroke trial for NTx(R)-265, the Company's ability to continue further stroke studies is uncertain at this time due to its limited capital and the failure to meet the primary efficacy endpoint in the modified REGENESIS-Phase IIb stroke trial. Accordingly, the Board of Directors has decided to implement a cost-cutting program to preserve as much capital as possible while management pursues the end-of-Phase II meeting with the FDA. As part of this program, the employment contracts for each of the senior officers of the Company (CEO, CFO, VP Product, Development and VP, Commercial Planning) have been terminated effective June 30, 2010. Alan Moore, the current CEO, and Barry Herring, the current CFO have agreed to stay on with the Company in their current capacities on a consulting basis for the following six months to assist the Company in its attempt to maximize the value of its intellectual property. The Company has made a similar consulting offer to Alan Davidoff, the current VP, Product Development and expects to have a response next week. Also, as part of the cost cutting program, other staff positions will be eliminated or reduced, certain external research and service contracts will be terminated, and the Company will significantly reduce the size of its office space. The estimated cost of effecting the employee terminations and other cutbacks discussed above is approximately $540,000. Management estimates that after giving effect to the cost cutting program, the Company will have a cash balance of approximately $1.4 million at the end of 2010, with little or no severance, lease or other contractual obligations at such time. The Board believes that taking these steps now will put the Company in the strongest financial position to consider and pursue strategic alternatives for maximizing future shareholder value.
Board of Directors
Bob Rieder resigned as a director of the Company effective June 24, 2010. The remaining Board members have verbally indicated their intention to remain on the Board until at least the end of 2010.
Outlook for Remainder of 2010
During the next six months, management will focus its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx(R)-265 stroke therapy, as discussed above. This is expected to be a low-cost initiative. At the same time, management and the Board will review alternatives for pursuing the traumatic brain injury ("TBI") and multiple sclerosis ("MS") study opportunities that have been discussed in the past. The focus in this regard will be to determine the best way to finance such studies through to their completion. In addition to the foregoing, management and the Board will also consider other strategic alternatives for the Company. This might involve the engagement of a financial advisor and/or the appointment of a Special Committee of the Board. No such steps have been taken at this time as the current priority is to implement the cost cutting program described above and allow management to begin pursuing the initiatives discussed in this press release. Further updates will be announced as developments warrant.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit http://www.stemcellthera.com.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements, including specifically estimated expenses and future cash balances, involve risk and uncertainties, which may cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
woodstock135
14 years ago
Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent
16 minutes ago - ACQUIREMEDIA
CALGARY, ALBERTA--(Marketwire - June 8, 2010) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted U.S. Patent 7,704,737 entitled, "Oligodendrocyte Production from Multipotent Neural Stem Cells". The claims cover the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Dr. Alan Moore, President and CEO, commented as follows:
"The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT's overall intellectual property portfolio."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
403-245-5495 ext.224
amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
403-245-5495 ext. 230
adasilva@stemcellthera.com
www.stemcellthera.com
Source: Stem Cell Therapeutics Corp.
janetcanada
14 years ago
On Stock House by nu2this -
Finally someone is showing consideration:
Like everyone else here, I have (and still have) shares in SSS and yes, like everyone else, I was shocked when i opened the stocks this morning. We are all reeling because we believed we were going to have our way of life changed and visions of new cars, trips, bigger homes etc danced in our heads. Knowing how WE feel, try to think about how the staff at SCT feels. They have just been hit in the stomach with a wrecking ball. Their hopes/dreams have been kicked huge and THEIR credibility is definitely on the line here, not to mention the possible repercussions of everyone glaring, "Failure!". You just have to believe those people are in the backroom furiously going over all of the data/stats etc and are discussing every possibility of why the results are as they showed up. I am an eternal optimist and I believe things will be explained and the company will rebound on some lever. Ok, call me naive, but being negative at this point wil do absolutely nothing for anyone involved. Keep the faith, as dim as it may seem right now. Hugs to all.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
MinnieM
13 years ago
Hot Features
Premium
